Payment overview · 2025
General Payments
$97.49
4 reported records · 3 companies
Healthcare provider profile · identity verified
Samuel H Peeples, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, MS · NPI 1659443836
Verified facts
What the public records show
CMS Open Payments records show Samuel H Peeples, M.D. received $97.49 in general payments during 2025 across 4 reported records.
Stryker Corporation accounted for 56.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $55.45 | 56.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.80 | 23.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.24 | 19.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.49 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $31.38 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 831 | 240 |
| Atorvastatin Calcium | Atorvastatin Calcium | 700 | 201 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 146 |
| Losartan Potassium | Losartan Potassium | 446 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 113 |
| Pravastatin Sodium | Pravastatin Sodium | 354 | 98 |
| Omeprazole | Omeprazole | 326 | 98 |
| Lisinopril | Lisinopril | 318 | 90 |
| Metformin Hcl | Metformin Hcl | 315 | 89 |
| Potassium Chloride | Potassium Chloride | 226 | 76 |
| Ipratropium Bromide | Ipratropium Bromide | 215 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 65 |
| Eliquis | Apixaban | 201 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 183 | 61 |
| Gabapentin | Gabapentin | 182 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 54 |
| Ezetimibe | Ezetimibe | 166 | 48 |
| Alendronate Sodium | Alendronate Sodium | 148 | 46 |
| Sertraline Hcl | Sertraline Hcl | 144 | 46 |
| Simvastatin | Simvastatin | 142 | 45 |
| Furosemide | Furosemide | 141 | 51 |
| Allopurinol | Allopurinol | 140 | 39 |
| Carvedilol | Carvedilol | 139 | 36 |
| Jardiance | Empagliflozin | 134 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 32 |
| Famotidine | Famotidine | 119 | 36 |
| Spironolactone | Spironolactone | 119 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 38 |
| Metformin Hcl Er | Metformin Hcl | 100 | 30 |
| Ozempic | Semaglutide | 90 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 24 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 24 |
| Fenofibrate | Fenofibrate | 74 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Glimepiride | Glimepiride | 72 | 24 |
| Meloxicam | Meloxicam | 70 | 22 |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Atenolol | Atenolol | 64 | 17 |
| Alprazolam | Alprazolam | 56 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Finasteride | Finasteride | 50 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 48 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 32 |
| Buspirone Hcl | Buspirone Hcl | 46 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 11 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 11 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Prolia | Denosumab | 23 | 13 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 13 |
| Pregabalin | Pregabalin | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.49 · 4 records | Stryker Corporation | ARTIX MT, CLOTTRIEVER BOLD CATHETER, INTELLIS ADAPTIVESTIM, VOQUEZNA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error